Allspring Global Investments Holdings LLC trimmed its holdings in IRadimed Co. (NASDAQ:IRMD – Get Rating) by 4.5% during the third quarter, Holdings Channel reports. The institutional investor owned 62,625 shares of the medical equipment provider’s stock after selling 2,948 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in IRadimed were worth $1,882,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in the business. Resource Consulting Group Inc. purchased a new stake in shares of IRadimed in the third quarter valued at about $3,848,000. Bares Capital Management Inc. raised its holdings in shares of IRadimed by 109.2% in the second quarter. Bares Capital Management Inc. now owns 129,240 shares of the medical equipment provider’s stock valued at $4,386,000 after purchasing an additional 67,454 shares during the last quarter. Aviva PLC raised its holdings in shares of IRadimed by 334.5% in the second quarter. Aviva PLC now owns 61,259 shares of the medical equipment provider’s stock valued at $2,079,000 after purchasing an additional 47,159 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of IRadimed by 9.6% in the first quarter. Vanguard Group Inc. now owns 339,257 shares of the medical equipment provider’s stock valued at $15,212,000 after purchasing an additional 29,696 shares during the last quarter. Finally, Prudential Financial Inc. raised its holdings in shares of IRadimed by 368.6% in the first quarter. Prudential Financial Inc. now owns 36,740 shares of the medical equipment provider’s stock valued at $1,647,000 after purchasing an additional 28,900 shares during the last quarter. 50.03% of the stock is owned by institutional investors.
Insider Activity at IRadimed
In related news, Director Anthony Vuoto sold 1,000 shares of the company’s stock in a transaction that occurred on Monday, December 5th. The stock was sold at an average price of $28.55, for a total value of $28,550.00. Following the transaction, the director now owns 14,121 shares in the company, valued at $403,154.55. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 43.70% of the stock is owned by company insiders.
IRadimed Price Performance
IRadimed (NASDAQ:IRMD – Get Rating) last released its earnings results on Thursday, November 3rd. The medical equipment provider reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.23 by $0.04. IRadimed had a net margin of 25.85% and a return on equity of 19.24%. The firm had revenue of $13.41 million for the quarter, compared to analysts’ expectations of $13.17 million. As a group, research analysts expect that IRadimed Co. will post 0.98 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Separately, StockNews.com began coverage on shares of IRadimed in a report on Wednesday, October 12th. They issued a “buy” rating for the company.
IRadimed Company Profile
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging (MRI) compatible medical devices. It also provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
- Get a free copy of the StockNews.com research report on IRadimed (IRMD)
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
Receive News & Ratings for IRadimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRadimed and related companies with MarketBeat.com's FREE daily email newsletter.